Search

Yan Chen,1,2 Xinyu Cui,2 Jiahuan Zhuoma,2 Fang Zhu,2 Li Luo,3 Juan Xie,2 Yongzhong Cheng2 1Institute of Hospital Management, West China Hospital of Sichuan University, Chengdu, People’s Republic of China; 2The Commission for Discipline Inspection, West China Hospital of Sichuan University, Chengdu, People’s Republic of China; 3Industrial Engineering and Engineering Management Department, College of Business of Sichuan University, Chengdu, People’s Republic of ChinaCorrespondence: Li Luo; Juan Xie, Industrial Engineering and Engineering Management Department, Business School of Sichuan University, Chengdu, People’s Republic of China, Email luolicc@scu.edu.cn; 857538446@qq.comPurpose: To examine how employees perceive corruption risks in their hospital and to provide recommendations for good governance in that hospital.Methods: The “Questionnaire of Corruption Risk Perception Index in Public Hospitals” was designed and a questionnaire survey was conducted online from April 17 to 30, 2020 in West China Hospital of Sichuan University, to explore employees’ assessment of corruption risk. Employees were asked to evaluate the likelihood and impact of corruption risk to form a corruption risk perception index (CRPI). Related factors were examined in multifactor analysis.Results: A total of 5525 employees participated in the survey. Among all 15 kinds of risks, unreasonable personnel changes (CRPI=8.24), no collective discussion about important issues (CRPI=7.95), and violating the individual moral character (CRPI=7.85) were the top 3 ones that participants rated highest, while illegal procurement (CRPI=7.38), violating teaching ethics (CRPI=7.12) and medical ethics (CRPI=6.93) were rated lowest. Corruption risks were mainly concentrated in internal management, treatment regulation, professional conduct, and external cooperation. The OR value that the CRPI of leaders was 0.768 times that of ordinary employ

Yuzhu Hu,1,2 Mengni Ran,1 Bilan Wang,3 Yunzhu Lin,3 Yongzhong Cheng,1 Songping Zheng1 1Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China; 2Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of ChinaCorrespondence: Yongzhong Cheng; Songping Zheng Tel +86 28 8516 4063Email chengyz@scu.edu.cn; 13618088051@163.comIntroductions: Ovarian cancer is a stubborn malignancy of gynecological system with a high mortality rate. Docetaxel (DTX), the second-generation of anti-tumor drug Taxane, has shown superior efficacy over classic paclitaxel (PTX) in certain cancers. However, its clinical application is hindered by poor bioavailability. The natural spice extract curcumin (Cur) has been discovered to improve the bioavailability of DTX. Therefore, it is meaningful to develop a combined drug strategy of DTX and Cur with methoxy poly (ethylene glycol)-poly (L-lactic acid) (MPEG-PLA) copolymers in ovarian cancer therapy.Methods: Injectable DTX-Cur/M nanomicelles were synthesized and characterized in the study. The molecular interactions between DTX, Cur and copolymer were simulated and the drug release behavior was investigated. The anti-tumor activity and anti-tumor mechanisms of DTX-Cur/M were evaluated and explored in both cells and mice model of xenograft human ovarian cancer.Results: DTX-Cur/M nanomicelles with an average particle size of 37.63 nm were obtained. The drug release experiment showed sustained drug release from DTX-Cur/M nanomicelles. The MTT assay and apoptotic study indicated that DTX-Cur/M exhibited stronger

Yuzhu Hu, 1–3 Yihong He, 1–3 Jianrui Ji, 1 Songping Zheng, 1–3 Yongzhong Cheng 1–3 1Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China; 2Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of ChinaCorrespondence: Songping Zheng; Yongzhong ChengDepartment of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of ChinaTel +86 28 8516 4063Email 13618088051@163.com; chengyz@scu.edu.cnIntroduction: Curcumin (Cur) is a natural extract of Asian spice Curcumin longa, showing multi-targeting capability and low toxicity in anti-tumor activities. The low bioavailability restricts its application as a therapeutic agent. Folate (FA) receptors are highly expressed in many malignant tumors while low expressed in normal tissue. Herein, we developed a self-assembled FA modified MPEG-PCL micelle to incorporate Cur (FA/Nano-Cur) and applied it for colorectal cancer therapy.Methods: We prepared FA/Nano-Cur micelles and identified their characteristics. The drug release behavior, pharmacokinetics and in vitro anti-tumor activities of FA/Nano-Cur were studied. Furthermore, the in vivo anti-tumor ability assessment and anti-tumor mechanisms investigation were carried out in murine colorectal cancer model.Results: FA/Nano-Cur micelles had an average particle size of 30.47 nm. Elongated T 1/2 and larger AUC were found in FA/Nano-Cur group than that in the Free Cur group. MTT assay and apoptotic study indicated the

Yuzhu Hu,1,2 Mengni Ran,1 Bilan Wang,3 Yunzhu Lin,3 Yongzhong Cheng,1 Songping Zheng1 1Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China; 2Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu 610041, People’s Republic of ChinaCorrespondence: Yongzhong Cheng; Songping Zheng Tel +86 28 8516 4063Email chengyz@scu.edu.cn; 13618088051@163.comIntroductions: Ovarian cancer is a stubborn malignancy of gynecological system with a high mortality rate. Docetaxel (DTX), the second-generation of anti-tumor drug Taxane, has shown superior efficacy over classic paclitaxel (PTX) in certain cancers. However, its clinical application is hindered by poor bioavailability. The natural spice extract curcumin (Cur) has been discovered to improve the bioavailability of DTX. Therefore, it is meaningful to develop a combined drug strategy of DTX and Cur with methoxy poly (ethylene glycol)-poly (L-lactic acid) (MPEG-PLA) copolymers in ovarian cancer therapy.Methods: Injectable DTX-Cur/M nanomicelles were synthesized and characterized in the study. The molecular interactions between DTX, Cur and copolymer were simulated and the drug release behavior was investigated. The anti-tumor activity and anti-tumor mechanisms of DTX-Cur/M were evaluated and explored in both cells and mice model of xenograft human ovarian cancer.Results: DTX-Cur/M nanomicelles with an average particle size of 37.63 nm were obtained. The drug release experiment showed sustained drug release from DTX-Cur/M nanomicelles. The MTT assay and apoptotic study indicated that DTX-Cur/M exhibited stronger

Yuzhu Hu, 1–3 Yihong He, 1–3 Jianrui Ji, 1 Songping Zheng, 1–3 Yongzhong Cheng 1–3 1Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China; 2Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China; 3Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of ChinaCorrespondence: Songping Zheng; Yongzhong ChengDepartment of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of ChinaTel +86 28 8516 4063Email 13618088051@163.com; chengyz@scu.edu.cnIntroduction: Curcumin (Cur) is a natural extract of Asian spice Curcumin longa, showing multi-targeting capability and low toxicity in anti-tumor activities. The low bioavailability restricts its application as a therapeutic agent. Folate (FA) receptors are highly expressed in many malignant tumors while low expressed in normal tissue. Herein, we developed a self-assembled FA modified MPEG-PCL micelle to incorporate Cur (FA/Nano-Cur) and applied it for colorectal cancer therapy.Methods: We prepared FA/Nano-Cur micelles and identified their characteristics. The drug release behavior, pharmacokinetics and in vitro anti-tumor activities of FA/Nano-Cur were studied. Furthermore, the in vivo anti-tumor ability assessment and anti-tumor mechanisms investigation were carried out in murine colorectal cancer model.Results: FA/Nano-Cur micelles had an average particle size of 30.47 nm. Elongated T 1/2 and larger AUC were found in FA/Nano-Cur group than that in the Free Cur group. MTT assay and apoptotic study indicated the